The company is actually called Ascendis Health, but one look at a share price chart and you’ll understand why I laughed when an ex-banking colleague called it Descendis Health in a chat we had a few weeks ago. With a nod to his genius, I’ve borrowed the name. If there was ever a poster child for a high-risk acquisitive strategy …
View PostThe company is actually called Ascendis Health, but one look at a share price chart and you’ll understand why I laughed when an ex-banking colleague called it Descendis Health in a chat we had a few weeks ago. With a nod to his genius, I’ve borrowed the name. If there was ever a poster child for a high-risk acquisitive strategy …
View PostThe company is actually called Ascendis Health, but one look at a share price chart and you’ll understand why I laughed when an ex-banking colleague called it Descendis Health in a chat we had a few weeks ago. With a nod to his genius, I’ve borrowed the name. If there was ever a poster child for a high-risk acquisitive strategy …
View PostTesla will be admitted to the S&P500 and will immediately jump into a top ten spot on the index based on a market capitalisation that appears to be marching towards $500bn. The Index Committee was suspicious back in September when Tesla achieved profitability over four consecutive quarters, electing not to include Tesla in the index despite the criteria being met. …
View PostTesla will be admitted to the S&P500 and will immediately jump into a top ten spot on the index based on a market capitalisation that appears to be marching towards $500bn. The Index Committee was suspicious back in September when Tesla achieved profitability over four consecutive quarters, electing not to include Tesla in the index despite the criteria being met. …
View Post